New Treatment Strategy Offers Hope To Rheumatoid Arthritis Patients Who Failed All Other Therapies
Wednesday, June 17, 2009 - 21:35
in Health & Medicine
Rheumatoid arthritis patients who failed to respond to initial treatment with rituximab (a chimeric monoclonal antibody against the protein CD20) can still be successfully re-treated with a second course of RTX after six months, according to new results.
Read the whole article on Science Daily
More from Science Daily
Related
- New treatment strategy offers hope to RA patients who failed all other therapiesFri, 12 Jun 2009, 10:08:42 EDT
- Rheumatoid arthritis breakthroughTue, 11 Nov 2008, 20:22:03 EST
- 30 percent RA patients refractory to anti-TNFs achieve disease remission with tocilizumab plus methoFri, 13 Jun 2008, 14:23:23 EDT
- Gene therapy demonstrates benefit in patients with rheumatoid arthritisMon, 26 Jan 2009, 15:29:37 EST
- Type of rheumatoid arthritis medication may be associated with increased risk for shinglesTue, 17 Feb 2009, 17:07:55 EST